Roberto de Jesús Sandoval-Muñiz

Dr. Roberto de Jesús Sandoval-Muñiz

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2017 in Hematology
Verified
Journal Article
Open access
Aniel Jessica Leticia Brambila-TapiaAniel Jessica Leticia Brambila-Tapia
Aniel Jessica Leticia Brambila-Tapia
JGJOSÉ ELÍAS GARCÍA-ORTÍZ
JOSÉ ELÍAS GARCÍA-ORTÍZ
PBPascal Brouillard
Pascal Brouillard
HNHa-Long Nguyen
Ha-Long Nguyen
Miikka VikkulaMiikka Vikkula
Miikka Vikkula
LALisette Arnaud-Lopez
Lisette Arnaud-Lopez
Introduction: GATA2 mutations are associated with several conditions, including Emberger syndrome which is the association of primary lymphedema with hematological anomalies and an increased risk for myelodysplasia and leukemia. Objective: To describe a family with Emberger syndrome with incomplete penetrance. Methods: A DNA sequencing of GATA2 gene was performed in the parents and offspring (five individuals in total). Results: The family consisted of 5 individuals with a GATA2 null mutation (c.130G>T, p.Glu44*); three of them were affected (two of which were deceased) while two remained unaffected at the age of 40 and 13 years old. The three affected siblings (two boys and one girl) presented with lymphedema of the lower limbs, recurrent warts, epistaxis and recurrent infections. Two died due to hematological abnormalities (AML and pancytopenia). In contrast, the two other family members who carry the same mutation (the mother and one brother) have not presented any symptoms and their blood tests remain normal. Discussion: Incomplete penetrance may indicate that GATA2 haploinsufficiency is not enough to produce the phenotype of Emberger syndrome. It could be useful to perform whole exome or genome sequencing, in cases where incomplete penetrance or high variable expressivity is described, in order to probably identify specific gene interactions that drastically modify the phenotype. In addition, skewed gene expression by an epigenetic mechanism of gene regulation should also be considered.

19 June 2025 in Gaceta Médica de México
Verified
Journal Article
Open access
PDF file
CGChristopher A. Gutiérrez-García
Christopher A. Gutiérrez-García
MGMartín R. Gutiérrez-Jiménez
Martín R. Gutiérrez-Jiménez
Roberto de Jesús Sandoval-MuñizRoberto de Jesús Sandoval-Muñiz
Roberto de Jesús Sandoval-Muñiz
Raúl Cuauhtémoc Baptista RosasRaúl Cuauhtémoc Baptista Rosas
Raúl Cuauhtémoc Baptista Rosas
Background: Diabetes, which is caused by environmental and genetic factors, has a high global prevalence (10.5%). Some single nucleotide variants (SNVs) modi...

29 March 2026 in Pharmacy
Verified
Journal Article
Open access
PDF file
CRCarlos Estrada-De La Rosa
Carlos Estrada-De La Rosa
FAFelipe Avalos
Felipe Avalos
Nancy Evelyn Navarro RuizNancy Evelyn Navarro Ruiz
Nancy Evelyn Navarro Ruiz
ELErika Fabiola López-Villalobos
Erika Fabiola López-Villalobos
Roberto de Jesús Sandoval-MuñizRoberto de Jesús Sandoval-Muñiz
Roberto de Jesús Sandoval-Muñiz
Raymundo Escutia GutiérrezRaymundo Escutia Gutiérrez
Raymundo Escutia Gutiérrez
Background/Objectives: Gabapentinoids are first-line treatments for neuropathic pain (NP); however, real-world evidence regarding their safety and effectiveness in complex clinical populations remains limited. This study aimed to evaluate the effectiveness and safety profile of gabapentinoid therapy in patients managed within a specialized pain relief institution. Methods: A retrospective cohort study (n = 109) was conducted (January 2024 to December 2024). Effectiveness was assessed via DN4 and VAS over one year. Time to improvement was analyzed using Kaplan–Meier curves. Results: The cohort (mean age 66.2 ± 15.3 years) presented 100% comorbidity and polypharmacy (66.1% opioids; 67.9% antidepressants). Although all patients showed improvement, only 35.8% achieved “maximal improvement.” Pregabalin demonstrated faster VAS reduction than gabapentin (p = 0.029), though long-term success was comparable (p = 0.30). Significantly, 100% of patients reported at least one adverse drug event (ADE), primarily somnolence (66.1%), though no serious ADEs occurred. Lower baseline pain scores were significant predictors of therapeutic success. Conclusions: Gabapentinoids are effective for long-term NP management; however, their use is consistently associated with non-serious ADEs. In specialized settings characterized by extensive CNS-active polypharmacy, proactive pharmacovigilance and multidisciplinary oversight are essential to balance analgesic effectiveness with medication safety.

14 February 2022 in Revista de Educación E Investigación En Emergencias
Verified
Journal Article
Closed access
LRLeopoldo J. Rodríguez-Cruz
Leopoldo J. Rodríguez-Cruz
GCGerardo Capiz-Lemus
Gerardo Capiz-Lemus
Roberto de Jesús Sandoval-MuñizRoberto de Jesús Sandoval-Muñiz
Roberto de Jesús Sandoval-Muñiz